Meclizine as a Potential Smoking Cessation Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

July 31, 2013

Conditions
Smoking Cessation
Interventions
DRUG

Meclizine

Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.

DRUG

Nicotine Patch

"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."

DRUG

Placebo

Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.

Trial Locations (4)

27103

Duke Center for Nicotine and Smoking Cessation Research, Winston-Salem

27609

Duke Center for Nicotine and Smoking Cessation Research, Raleigh

27705

Duke Center for Nicotine and Smoking Cessation Research, Durham

28210

Duke Center for Nicotine and Smoking Cessation Research, Charlotte

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Philip Morris USA, Inc.

INDUSTRY

lead

Duke University

OTHER

NCT01443858 - Meclizine as a Potential Smoking Cessation Treatment | Biotech Hunter | Biotech Hunter